Universal Health Services
UHS
174.62
-2.46
-1.39%
Universal Health Services
US · UHS
#1440 by market cap
Listed 1970
174.62
-2.46
-1.39%
Live - 5344 symbols - heartbeat 61s ago
· 2026-10-08 06:08
Pre-market
174.00
-0.36%
After-hours
174.62
0.00%
- Market cap
- 10.29B
- P/E (TTM)i
- 7.13
- P/Bi
- 1.37
- EPSi
- 23.10
- Div yieldi
- 0.46%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on UHS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.04, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.71% YoY
Margins
- Gross margin
- 90.45%
- Operating margin
- 11.48%
- Net margin
- 8.57%
Key ratios & quality
- Enterprise valuei
- 14.98B
- PEG ratioi
- 0.24
- Altman Z-Scorei
- 3.04
PEG uses trailing P/E against the 3-year net income growth rate (30.13%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.77B | 11.38B | 11.56B | 12.64B | 13.40B | 14.28B | 15.83B | 17.36B |
| Gross profit | 9.60B | 10.13B | 10.27B | 11.21B | 11.93B | 12.75B | 14.24B | 15.71B |
| Selling & admin expenses | 5.36B | 5.70B | 5.73B | 6.28B | 6.89B | 7.25B | 7.67B | 8.23B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.18B | 1.22B | 1.36B | 1.36B | 1.00B | 1.18B | 1.68B | 1.99B |
| Pretax profit | 1.03B | 1.07B | 1.25B | 1.29B | 866.26M | 940.43M | 1.50B | 1.97B |
| Tax | 236.64M | 238.79M | 299.29M | 305.68M | 209.28M | 221.12M | 334.83M | 460.96M |
| Net profit | 797.88M | 827.54M | 952.79M | 987.63M | 656.98M | 719.31M | 1.16B | 1.51B |
| Basic EPS | 8 | 9 | 11 | 12 | 9 | 10 | 17 | 23 |
| Diluted EPS | 8.31 | 9.13 | 10.99 | 11.82 | 9.14 | 10.23 | 16.82 | 23.10 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.10B | 4.28B | 4.50B | 4.49B | 4.50B | 4.64B |
| Gross profit | 3.70B | 3.87B | 4.08B | 4.06B | 4.07B | 4.21B |
| Selling & admin expenses | 1.99B | 2.05B | 2.11B | 2.09B | 2.13B | 2.18B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 454.83M | 500.27M | 521.69M | 517.23M | 502.86M | 516.68M |
| Pretax profit | 420.43M | 473.39M | 496.89M | 581.44M | 469.12M | 479.13M |
| Tax | 98.80M | 110.77M | 117.78M | 133.61M | 110.44M | 114.54M |
| Net profit | 321.63M | 362.61M | 379.11M | 447.84M | 358.68M | 364.59M |
| Basic EPS | 5 | 5 | 6 | 7 | 6 | 6 |
| Diluted EPS | 4.80 | 5.43 | 5.86 | 7.06 | 5.65 | 5.98 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.94B | 1.92B | 3.28B | 2.26B | 2.54B | 2.81B | 2.82B | 3.41B |
| Cash & ST investments | 105.22M | 61.27M | 1.22B | 115.30M | 102.82M | 119.44M | 125.98M | 137.80M |
| Inventory | 148.21M | 159.89M | 190.42M | 206.84M | 218.52M | 216.99M | 220.94M | 232.11M |
| Total assets | 11.27B | 11.67B | 13.48B | 13.09B | 13.49B | 13.97B | 14.47B | 15.53B |
| Total current liabilities | 1.45B | 1.56B | 2.48B | 1.98B | 1.91B | 2.01B | 2.21B | 3.24B |
| Short-term debt | 63.45M | 143.99M | 391.79M | 112.89M | 149.22M | 198.29M | 114.71M | 821.40M |
| Long-term debt | 3.94B | 3.90B | 3.52B | 4.14B | 4.73B | 4.79B | 4.46B | 4.00B |
| Total liabilities | 5,795,395,000.00 | 6,085,046,000.00 | 7,070,343,000.00 | 6,895,371,000.00 | 7,524,143,000.00 | 7,765,696,000.00 | 7,706,933,000.00 | 8,118,185,000.00 |
| Total equity | 5.47B | 5.58B | 6.41B | 6.20B | 5.97B | 6.20B | 6.76B | 7.41B |
| Retained earnings | 5.79B | 5.93B | 6.75B | 6.60B | 6.53B | 6.80B | 7.37B | 7.99B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.08B | 2.99B | 3.26B | 3.41B | 3.50B | 3.68B |
| Cash & ST investments | 126.75M | 137.60M | 112.90M | 137.80M | 119.03M | 138.80M |
| Inventory | 221.99M | 222.78M | 226.66M | 232.11M | 229.42M | 234.09M |
| Total assets | 14.88B | 14.99B | 15.34B | 15.53B | 15.68B | 15.94B |
| Total current liabilities | 2.33B | 2.32B | 3.16B | 3.24B | 3.24B | 3.30B |
| Short-term debt | 116.34M | 114.07M | 813.52M | 821.40M | 829.14M | 842.77M |
| Long-term debt | 4.61B | 4.54B | 3.95B | 4.00B | 3.95B | 4.08B |
| Total liabilities | 7,989,696,000.00 | 7,840,495,000.00 | 8,046,445,000.00 | 8,118,185,000.00 | 8,076,663,000.00 | 8,280,248,000.00 |
| Total equity | 6.89B | 7.15B | 7.30B | 7.41B | 7.60B | 7.66B |
| Retained earnings | 7.49B | 7.71B | 7.87B | 7.99B | 8.20B | 8.26B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.27B | 1.44B | 2.36B | 883.70M | 996.02M | 1.27B | 2.07B | 1.86B |
| Depreciation & amortization | 453.08M | 490.39M | 510.49M | 533.21M | 581.86M | 568.04M | 584.83M | 618.74M |
| Free cash flow | 463.07M | 782.96M | 1.63B | 28.04M | 262.02M | 524.74M | 1.12B | 824.55M |
| Dividends paid | -37.34M | -53.00M | -17.34M | -65.90M | -58.45M | -55.48M | -53.35M | -51.27M |
| Stock buybacks / issuance | -387.23M | -759.70M | -194.40M | -1.21B | -818.85M | -533.71M | -655.68M | -951.22M |
| Ending cash balance | 199.69M | 105.67M | 1.28B | 178.93M | 200.84M | 214.47M | 224.75M | 271.32M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 360.05M | 548.98M | 380.68M | 574.69M | 401.63M | 443.30M |
| Depreciation & amortization | 148.35M | 152.00M | 155.06M | 163.33M | 155.43M | 167.34M |
| Free cash flow | 121.02M | 282.96M | 133.11M | 287.45M | 179.86M | 210.32M |
| Dividends paid | -13.53M | -12.90M | -12.47M | -12.37M | -12.97M | -11.79M |
| Stock buybacks / issuance | -219.73M | -150.68M | -233.42M | -347.40M | -160.07M | -315.88M |
| Ending cash balance | 223.73M | 241.40M | 216.60M | 271.32M | 252.55M | 272.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 15.00 | 14.92 | 15.92 | 15.95 | 11.24 | 11.89 | 17.82 | 21.36 |
| ROA %i | 7.07 | 7.09 | 7.48 | 7.45 | 5.08 | 5.23 | 8.03 | 9.93 |
| ROIC %i | 9.73 | 9.77 | 10.02 | 9.93 | 7.03 | 7.68 | 11.09 | 13.34 |
| 5-year avg ROE %i | 15.89 | 15.75 | 15.53 | 15.52 | 14.61 | 13.98 | 14.56 | 15.65 |
| EBIT margin %i | 11.03 | 10.79 | 11.73 | 10.87 | 7.38 | 8.00 | 10.62 | 12.23 |
| FCF / sales %i | 4.91 | 6.81 | 13.62 | 0.22 | 1.96 | 3.67 | 7.10 | 4.75 |
| Current ratioi | 1.34 | 1.23 | 1.32 | 1.14 | 1.33 | 1.40 | 1.27 | 1.05 |
| Quick ratioi | 1.11 | 1.04 | 1.19 | 0.94 | 1.11 | 1.17 | 1.04 | 0.85 |
| Debt / assetsi | 35.49 | 36.94 | 31.12 | 34.82 | 39.06 | 38.42 | 34.25 | 33.27 |
| LT debt / equityi | 73.02 | 75.70 | 60.19 | 73.02 | 86.51 | 84.05 | 72.62 | 59.72 |
| Interest coveragei | 7.71 | 7.60 | 13.02 | 16.98 | 8.08 | 5.65 | 9.21 | 13.95 |
| Revenue CAGR (3Y) %i | 6.00 | 5.22 | 3.55 | 5.48 | 5.60 | 7.31 | 7.78 | 9.03 |
| Net income CAGR (3Y) %i | 4.64 | 5.07 | 7.86 | 8.34 | -6.06 | -8.73 | 4.82 | 30.13 |
| FCF CAGR (3Y) %i | 43.94 | 63.66 | 36.58 | -60.73 | -30.57 | -31.41 | 242.18 | 46.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 18.35 | 18.66 | 19.97 | 21.36 | 21.34 | 20.99 |
| ROA %i | 8.28 | 8.68 | 9.26 | 9.93 | 9.95 | 9.87 |
| ROIC %i | 11.32 | 11.74 | 12.41 | 13.34 | 13.36 | 13.24 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 10.89 | 11.12 | 11.65 | 12.23 | 12.22 | 12.03 |
| FCF / sales %i | 6.57 | 5.48 | 5.59 | 4.75 | 4.97 | 4.48 |
| Current ratioi | 1.32 | 1.29 | 1.03 | 1.05 | 1.08 | 1.12 |
| Quick ratioi | 1.09 | 1.05 | 0.85 | 0.85 | 0.88 | 0.89 |
| Debt / assetsi | 34.25 | 33.42 | 33.31 | 33.27 | 32.69 | 33.02 |
| LT debt / equityi | 73.36 | 69.61 | 59.94 | 59.72 | 57.56 | 58.82 |
| Interest coveragei | 10.32 | 11.71 | 13.20 | 13.95 | 14.56 | 14.23 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Acute Care Hospital Services is the largest reported line at 56.27% of revenue, across 3 reported segments.
- Behavioral Health Care Services follows at 43.66%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Acute Care Hospital Services56.27%
Behavioral Health Care Services43.66%
Quote time 2026-10-08 06:08:41 · For reference only, not investment advice and not tailored to your situation.